move hold lower pt deal
downgrad armo hold compani enter
definit agreement acquir buy hillik per share
all-cash deal expect deal close end month
w/out addit offer
armo own late-stag differenti immuno-oncolog pipelin armo
uniqu posit immuno-oncolog io compani captur market opportun
pegilodecakin pegyl human cytokin variou combin strategi
exhibit encourag efficaci signal tradit immune-insensit tumor type
refractori cancer patient hallmark low/neg level and/or low tumor
mutat burden tmb indic poor respons inhibitor therapi thu
armo hold potenti address market inaccess current therapi
nsclc main valu driver armo pdac pivot trial armo appear
track pivot sequoia trial panc cancer pdac posit outcom
achiev first interim futil analysi earli second interim analysi
expect bla submiss armo biggest opportun recent dose first
patient line nsclc pt low express
compar pegilodecakin pembro vs pembro therapi pt high
also process enrol pt soon
buy
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
folfox combin approv eu/u
pancreat cancer
combin therapi derisk
clinic data readout phase ii studi nsclc
combin therapi approv
second-lin nsclc us/eu
frontlin nsclc
folfox combin therapi pancreat
cancer fulli derisk price
combin therapi nsclc
combin therapi nsclc
pancreat nsclc derisk price
program rcc melanoma tnbc
folfox combin therapi unsuccess
pancreat cancer price
combin therapi unsuccess
nsclc price
expect folfox combo develop
success pancreat cancer
expect
nivolumab develop success non-smal cell
expect corner stone compon novel
combin therapi across broad rang tumor
enrol updat phase iib trial nsclc
initi trial renal cell cancer
initi data updat trial
second interim analysi sequoia pivot trial pancreat
cancer
bla submiss pancreat cancer
page
pleas see import disclosur inform page report
arriv price target base lli offer price acquisit previou dcf
model assum wacc current assum termin valu
outstand share driven sale pdac nsclc expect
first product approv potenti end lead indic pancreat
cancer follow approv differ set nsclc think second line nsclc
could come board first line indic approv occur
current assum peak ww sale risk-adjust arriv
sale nsclc assum peak ww risk-adj sale
deriv second line assum discount top-line revenu
second line indic first line nsclc assum risk discount given
higher hurdl relat price assum monthli price
 eu appear compar current price io agent
risk clinic failur patient enrol clinic trial may experi difficulti
varieti reason clinic develop activ could delay otherwis
regulatori failur fda could determin compani bla inadequ
could delay approv delay approv timelin could impact earn
commerci failur estim peak sale individu asset may reli
success company/partn receiv drug reimburs private/publ
sooner anticip
financ risk broad scope pivot trial undecid cost-shar plan
partner epacadostat place financ pressur armo go forward
page
pleas see import disclosur inform page report
